Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome#United_States#London#Fragile_X_Syndrome#Kaerus_Bioscience#KER-0193
Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome
Kaerus Bioscience's lead candidate KER-0193 receives Orphan Drug and Rare Pediatric Drug Designations from the FDA for treating Fragile X syndrome.
third-news.com
May 14, 2025 at 7:37 AM
Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome#United_States#London#Fragile_X_Syndrome#Kaerus_Bioscience#KER-0193